 Amryt Pharma PLC AIM:AMYT, NASDAQ:AMYT said its forecasts for 2021 revenues would be unaffected after the US Food and Drug Administration made a three-month extension to the review period for the new drug application NDA for its Oleogel-S10 for the treatment of junctional and dystrophic epidermolysis bullosa. This is a rare and distressing genetic skin disorder affecting young children and adults for which there is currently no approved treatment. 